SCHEMBL3645985

SCHEMBL3645985

CCCCCc1[nH]c2ccc(OC)cc2c1CCNC(C)=O

nearest known ligand 0.71

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 17/20 0.71
MTNR1B P49286 17/20 0.71
NQO2 P16083 3/20 0.67
CYP1A2 P05177 2/20 0.67
CYP3A4 P08684 2/20 0.67
CYP2D6 P10635 2/20 0.67
CYP2C9 P11712 2/20 0.67
CYP2C19 P33261 2/20 0.67
TSHR P16473 1/20 0.67
KDM4E B2RXH2 2/20 0.66
ALDH1A1 P00352 2/20 0.66
HPGD P15428 2/20 0.66
HSD17B10 Q99714 2/20 0.66
POLB P06746 1/20 0.66
MDM2 Q00987 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31543721 0.97 MTNR1A (0.72) MTNR1AMTNR1BNQO2CYP1A2CYP3A4
SCHEMBL31543684 0.92 MTNR1A (0.75) MTNR1AMTNR1BNQO2CYP1A2CYP3A4
SCHEMBL8686010 0.89 MTNR1A (0.77) MTNR1AMTNR1BNQO2CYP1A2CYP3A4
SCHEMBL30669508 0.83 MTNR1A (0.88) MTNR1AMTNR1BNQO2CYP1A2CYP3A4
SCHEMBL29138500 0.83 MTNR1A (0.88) MTNR1AMTNR1BNQO2CYP1A2CYP3A4
SCHEMBL15427952 0.83 MTNR1A (1.00) MTNR1AMTNR1BNQO2CYP1A2CYP3A4
SCHEMBL31543662 0.82 MTNR1A (0.55) MTNR1AMTNR1BNQO2CYP1A2CYP3A4
SCHEMBL9304037 0.82 MTNR1A (1.00) MTNR1AMTNR1BNQO2CYP1A2CYP3A4
SCHEMBL8946916 0.82 MTNR1A (1.00) MTNR1AMTNR1BNQO2CYP1A2CYP3A4
SCHEMBL31530479 0.82 MTNR1A (0.78) MTNR1AMTNR1BNQO2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674816-B2 Substituted melatonin derivatives, process for their preparation, and methods of use ABRAXIS BIOSCIENCE, LLC (US) 2010-03-09 US disclosed
EP-1701718-A4 SUBSTITUTED MELATONIN DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE ABRAXIS BIOSCIENCE LLC (US) 2009-06-24 EP disclosed
US-20070191463-A1 Substituted melatonin derivatives, process for their preparation, and methods of use ABRAXIS BIOSCIENCE, INC. (CA) 2007-08-16 US disclosed
EP-1701718-A2 SUBSTITUTED MELATONIN DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE Abraxis Bioscience, Inc. (US) 2006-09-20 EP disclosed
WO-2005062992-A2 SUBSTITUTED MELATONIN DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE ABRAXIS BIOSCIENCE, INC (US) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191463-A1 Substituted melatonin derivatives, process for their preparation, and methods of use MTNR1B, MTNR1A, CYP3A5 MTNR1A 2/4885MTNR1B 1/4885NQO2 588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.